TOP 10 – BIO-PHARMACEUTICAL COMPANIES

R & D PIPELINE SIZE: 196 EMPLOYEES: 51,000

CHIEF INFORMATION & DIGITAL OFFICER: DIOGO RAU

Indianapolis-based Eli Lilly is currently the world’ s most valuable drugmaker on the back of diabetes and obesity GLP-1 blockbusters such as Mounjaro and Zepbound, as well as recent growth in its Foundayo oral GLP-1 pill. Its pipeline spans metabolic disease, neuroscience, oncology and immunology, and 2026 has seen the company pursue an acquisition spree, including Orna Therapeutics, Centessa and AtaiBeckley, pushing further into cell therapy, radiopharmaceuticals, and Alzheimer’ s as it looks to diversify beyond its dominant obesity franchise.

150 years of everything else

CREDIT: ELI LILLY healthcare-digital. com 41